Aspheric-based procedures reduce need for re-treatments

Article

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations, according to a recent multicentre study conducted by Maria Clara Arbelaez, MD of the Muscat Eye Laser Center, Muscat, Oman and colleagues from the Charles University, Czech Republic.

The study of 183 eyes utilized the SCHWIND aberration-free treatment, which is designed to leave preoperative higher-order aberrations (HOAs) unchanged allowing patients to retain a habitual sight impression. All flaps were created using the Carriazo-Pendular microkeratome.

In 71% of eyes, the planned refractive result was achieved with a minimum deviation of ±0.25 D. Ninety-one percent were in the area of ±0.5 D and 100% of eyes achieved ±1 D.

Postoperative vision without aids compared with preoperative vision with glasses or contact lenses also increased significantly. At six-months follow-up, 86% of all eyes had achieved an uncorrected visual acuity (UCVA) of 20/20 or better, while only 69% had a best corrected visual acuity (BCVA) of 20/20 or better.

The study also demonstrated that the ORK-CAM software effectively aids the compensation of biomechanical changes of the cornea. At six-months follow-up, no growth of significant aberrations, such as coma or spherical aberration were observed.

It was concluded that the ESIRIS excimer laser and ORK-CAM software can provide good visual results as well as reducing the need for re-treatments.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.